Search clinical trials for: Lymphocyte injection of prophylactic donor (PDLI)

Total 147 results

Abramson Cancer Center of the University of Pennsylvania

Completed

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Institut Paoli-Calmettes

Not yet recruiting

Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML (ELIT-AML01)

Acute Myeloid Leukemia

France
St. Petersburg State Pavlov Medical University

Active, not recruiting

Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy

Hematologic Malignancy

Russian Federation
Rigshospitalet, Denmark

Recruiting

Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial (IDEAL)

AML/MDS

Denmark
Association for Training, Education, and Research...

Active, not recruiting

Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders (LY-SET-HAPLO)

Refractory or Relapsed Lymphoid Haemopathy

France
Association for Training, Education, and Research...

Completed

Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia (SET-HAPLO)

Refractory Acute Myeloid Leukemia

France
Washington University School of Medicine
National Cancer Institute (NCI); MacroGenics

Recruiting

Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Relapsed Acute Myeloid Leukemia

United States
University Hospital Tuebingen

Recruiting

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT (CD45RADLIHaplo)

Hematologic Malignancy

Germany
National Cancer Institute (NCI)

Terminated

Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemias | Multiple Myeloma With Plasmacytoma

United States
Istituto Clinico Humanitas

Completed

Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).

Infection | Graft Vs Host Disease | Hematological Malignancy | Bone Marrow Transplant Complications | Bone Marrow Transplant Infection

Italy
M.D. Anderson Cancer Center
Ziopharm Oncology

Completed

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Lymphoma | Leukemia

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Beth Israel Deaconess Medical Center; Brigham...

Completed

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

Hematologic Malignancy

United States
University of California, San Francisco
Johns Hopkins All Children's Hospital

Completed

A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Acute Leukemia | Chronic Myelogenous Leukemia | Biphenotypic Leukemia | Pre-leukemic Syndromes | Monosomy 7 | Bone Marrow Clonal Malformations

United States
Sumithira Vasu

Completed

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Minimal Residual Disease

United States
Masonic Cancer Center, University of Minnesota
Incyte Corporation

Completed

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloid and Monocytic Leukemia

United States
Groupe Francophone des Myelodysplasies
Astex Pharmaceuticals, Inc.

Active, not recruiting

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

AML | MDS

France
Kiadis Pharma

Terminated

Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Lymphoma | Myeloid Leukemia | Myeloproliferative Disorders | Multiple Myeloma | Myelodysplastic Syndrome | Lymphoblastic Leukemia

Canada, Netherlands, Germany, Belgium, United States, Italy, United Kingdom
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Not yet recruiting

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation

United States
Carlos Graux, MD, PhD
Celgene Corporation; Belgian Hematological Society

Completed

Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Belgium
Kiadis Pharma

Completed

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

Hematologic Diseases | Hematologic Malignancies

Canada
M.D. Anderson Cancer Center

Terminated

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Myeloma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Post Transplant Donor Lymphocyte Infusion

Multiple Myeloma | AML | Myelodysplastic Syndrome | Leukemia, Lymphocytic, Acute | Lymphomas | Leukemia, Myeloid, Chronic | Leukemia, Lymphocytic, Chronic

United States
Heinrich-Heine University, Duesseldorf
Celgene Corporation

Completed

Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT (AZALENA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

Germany
G. d'Annunzio University

Completed

Platelet Rich Fibrin in Soft Tissue Healing After Implant Uncovering

Healing Surgical Wounds

Italy
Wake Forest University Health Sciences

Terminated

Donor Lymphocyte Infusion After Alternative Donor Transplantation

Immunodeficiency

United States
Northwell Health
New York Blood Center

Completed

Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies

Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Nantes University Hospital

Terminated

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC (CYRIC)

Graft Versus Host Disease

France
The First Affiliated Hospital of Soochow University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

Acute Myeloid Leukemia

China
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia

United States
Monica Thakar

Completed

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | CNS Tumors

United States
Chinese PLA General Hospital

Unknown

Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies

Peripheral Blood Stem Cell Transplantation | Relapse | Donor Lymphocyte Infusion | Graft-versus-host Disease | Decitabine

China
Karolinska University Hospital
Nordic MDS Group

Recruiting

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Myelodysplastic Syndromes | Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts | Mixed Myelodysplastic/Myeloproliferative Disease

Sweden
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States
University of California, San Francisco
Hellman Foundation

Completed

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

Juvenile Myelomonocytic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Acute Lymphoid Leukemia

United States
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Lymphoma | Leukemia | Myeloproliferative Disorders | Myelodysplastic Syndrome | Multiple Myleoma

United States
Groupe Francophone des Myelodysplasies
AbbVie

Recruiting

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

AML | MDS

France
Antonio M Jimenez Jimenez
AbbVie

Not yet recruiting

Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Acute Myeloid Leukemia

United States
Incheon St.Mary's Hospital

Unknown

Continuous Infusion of Palonosetron for Preventing of Postoperative Nausea and Vomiting

Postoperative Nausea and Vomiting

Korea, Republic of
Shanghai General Hospital, Shanghai Jiao Tong University...
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Completed

CMV-CTL for the Treatment of CMV Infection After HSCT

Cytomegalovirus Infections | Hematological Disease

China
First Affiliated Hospital of Guangxi Medical University

Unknown

Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism

Beta Thalassemia Major

China
St. Jude Children's Research Hospital

Active, not recruiting

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Severe Combined Immunodeficiency

United States
University of Michigan Rogel Cancer Center

Completed

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

Multiple Myeloma | Lymphoma, Low-Grade | Lymphocytic Leukemia, Chronic

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

Hematologic Malignancy

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome

United States
Hôpital du Valais
University of Lausanne Hospitals

Completed

Single Versus Multiple Injections for Axillary Plexus Block

Upper Extremity

Switzerland
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Acute Leukemia | Hematologic Malignancies | Myeloma | Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes | Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy

United States
Beijing Tsinghua Chang Gung Hospital
Beijing DCTY® Biotech Co.,Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Recurrent Glioblastoma
Sunshine Lake Pharma Co., Ltd.

Completed

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

Type 2 Diabetes

China
King's College Hospital NHS Trust

Unknown

Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (PRO-DLI)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Malignant Neoplasm

United States

Search clinical trials for: Lymphocyte injection of prophylactic donor (PDLI)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations